Stoke Therapeutics, Inc. STOK Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s financing cash flow?
- Stoke Therapeutics, Inc. (STOK) reported financing cash flow of $84.33M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Stoke Therapeutics, Inc.'s financing cash flow increased by 6037.3% year-over-year, from $1.37M to $84.33M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s financing cash flow has grown at a 195.1% compound annual growth rate (CAGR), from $1.28M to $97.39M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.